Investigation of Insulin Secretion in Glucose Tolerance Test by the Intake of Novel Imeglimin (Twymeeg)

[featured_image]
Download
Download is available until [expire_date]
  • Version
  • Download 10675
  • File Size 0.00 KB
  • File Count 1
  • Create Date August 24, 2022
  • Last Updated August 24, 2022

Investigation of Insulin Secretion in Glucose Tolerance Test by the Intake of Novel Imeglimin (Twymeeg)

Hiroshi BANDO1,2,3*, Hiroko OGAWA2, Hirohisa URASAKI3,4, Shinji NAGAHIRO2,5, Hiroko URASAKI3, Miwako NAKANISHI2, Osami WATANABE2
1Medical Research / Tokushima University, Tokushima, Japan
2Yoshinogawa Hospital, Tokushima, Japan
3Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Tokushima, Japan
4Nankai Hospital, Naruto city, Tokushima, Japan
5Emeritus Professor, Former Director of Tokushima University Hospital, Tokushima, Japan

Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 05 July 2022; Accepted date: 13 August 2022; Published date: 19 August 2022

Citation: Bando H, Ogawa H, Urasaki H, Nagahiro S, Urasaki H, Nakanishi W, Watanabe O. Investigation of Insulin Secretion in Glucose Tolerance Test by the Intake of Novel Imeglimin (Twymeeg). Asp Biomed Clin Case Rep. 2022 Aug 19;5(3):113-19.

Copyright © 2022 Bando H, Ogawa H, Urasaki H, Nagahiro S, Urasaki H, Nakanishi W, Watanabe O. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Imeglimin, Twymeeg, Type 2 Diabetes, 75g Oral Glucose Tolerance Test, Insulinogenic Index, Japan LCD Promotion Association

Abbreviations: T2D: Type 2 Diabetes; 75gOGTT: 75g Oral Glucose Tolerance Test; IGI: Insulinogenic Index; JLCDPA: Japan LCD Promotion Association

Abstract

Background: Recent pharmacological studies reveal imeglimin (Twymeeg) including dual mechanisms for stimulating insulin secretion and reducing insulin resistance.
Case Presentation: The case is a 62-year-old male with type 2 diabetes (T2D). He showed HbA1c 6.4% and started imeglimin. After 5 weeks, a 75g oral glucose tolerance test (75gOGTT) was conducted, and the biomarkers were compared with that of 6 months ago. Insulinogenic index (IGI) 0-30min was stable, but insulin secretion was increased during 30-60min and 60-120min.
Discussion: Previous studies of imeglimin revealed improved insulin secretion for GTT. Clinical progress will be followed up with detailed investigation of glucose and insulin variability.